American Society of Pediatric Hematology/Oncology

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
화요일, 11월 7, 2023
DLBCL, The Year's Best Science Fiction: Eleventh Annual Collection, MD Anderson Cancer Center, FDA, NSCLC, NYSE, PIN, University, IHC, S&M, EST, CD22, G&A, Mitsubishi Tanabe Pharma, Society, ASH, Environment, SOHO, Growth, ADC, Clinical trial, Follicular lymphoma, KAAG1, Rituximab, Pancreatic cancer, Lung cancer, Safety, Therapy, American Society of Pediatric Hematology/Oncology, Patient, Immunohistochemistry, AXL, Sarcoma, Bank, Pharmaceutical industry, Video game, Fine chemical, Camisole

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • Net product revenues were $14.3 million for the quarter ended September 30, 2023, compared to $21.3 million for the same quarter in 2022.
  • S&M expenses were $13.7 million for the quarter ended September 30, 2023, compared to $16.8 million for the same quarter in 2022.
  • G&A expenses were $9.4 million for the quarter ended September 30, 2023, compared to $19.6 million for the same quarter in 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Retrieved on: 
목요일, 11월 2, 2023
Trial of the century, OH, Event, Safety, Sickle cell disease, Society, ASH, Senior, American Society of Pediatric Hematology/Oncology, Caregiver, Fetal hemoglobin, Editas Medicine, Patient, Blood, Pharmaceutical industry, Nursing, Blood product, Edith A. Perez

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the RUBY trial of EDIT-301 in patients with severe sickle cell disease and from the EdiTHAL trial of EDIT-301 in patients with transfusion-dependent beta thalassemia has been accepted for a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, CA, and online.

Key Points: 
  • Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m.
  • Editas Medicine will also host a Company-sponsored webinar on Monday, December 11, at 1:00 p.m.
  • ET to discuss the RUBY and EdiTHAL clinical data.
  • Clinical data on six patients, including at least five months data from the first two patients treated.

Rady Children's Researcher Awarded $4 Million

Retrieved on: 
화요일, 10월 10, 2023
Parent, Incidence, Hospital, University of California, San Diego, Biomedical Research, News, American Society of Pediatric Hematology/Oncology, Mentorship, Pediatrics, Moores Cancer Center, Imperial, National Cancer Institute, University, Survival, Lymphoma, Medical director, NCI, Rady Children's Hospital, Clinical trial, Associate, SAN, Leukemia, Bangladesh Technical Education Board, U.S. News & World Report, Research, NIH, MAS, Nursing, Birth control, MD, Cancer

SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- The National Institutes of Health (NIH) and the National Cancer Institute (NCI) recently awarded a $4 million Research Project Grant (RO1) to Paula Aristizabal, MD, MAS, pediatric oncologist at Rady Children's Hospital-San Diego and Associate Professor of Pediatrics in Pediatric Hematology/Oncology at the University of California San Diego and Moores Cancer Center to expand a pilot program aimed at improving diverse participation in pediatric cancer clinical trials. 

Key Points: 
  • Curebound , a San Diego-based philanthropic organization that raises and invests strategic funding in translational cancer research projects, funded the program with a $125,000 medical grant.
  • Based on the success of that program, Dr. Aristizabal and her team were awarded the NIH/NCI grant to implement a culturally and linguistically tailored peer-navigation intervention to increase minority participation in pediatric cancer clinical trials.
  • ‌About Rady Children's Hospital-San Diego:
    ‌ Rady Children's Hospital-San Diego is the largest children's hospital on the West Coast and one of the nation's top pediatric health care systems.
  • Rady Children's is a nonprofit organization that relies on donations to support its mission.

NCCN Senior Director Evelyn Handel Zapata is Named a '40 Under 40 in Cancer: Emerging Leader' for Milestone Work Improving Safe Use of Chemotherapy

Retrieved on: 
월요일, 9월 25, 2023
BCPS, Doctor of Pharmacy, Fred Hutchinson Cancer Research Center, BeiGene, HOPA, Journal of the National Comprehensive Cancer Network, Pharmacy, HIT, NCCN, Pharmacist, MD, Swim Across America, International Society, Safety, American Society of Pediatric Hematology/Oncology, Medical device, Pharmaceutical industry, Nursing, Takeda, Drug, Cancer

PLYMOUTH MEETING, Pa., Sept. 25, 2023 /PRNewswire/ -- Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader at a national reception in Chicago in June. This achievement comes as the NCCN Chemotherapy Order Templates (NCCN Templates®) program celebrates its 15th anniversary and launches new resources for a type of pediatric lymphoma today.

Key Points: 
  • PLYMOUTH MEETING, Pa., Sept. 25, 2023 /PRNewswire/ -- Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader at a national reception in Chicago in June.
  • This achievement comes as the NCCN Chemotherapy Order Templates ( NCCN Templates ®) program celebrates its 15th anniversary and launches new resources for a type of pediatric lymphoma today.
  • "Evelyn's work at NCCN has helped advance pharmacist involvement... on important national guidelines."
  • 40 Under 40 in Cancer is an awards initiative that recognizes contributions being made across the field of cancer by rising stars and emerging leaders under the age of 40.

The Inner Circle Acknowledges, James C. Lasker as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology

Retrieved on: 
화요일, 9월 5, 2023
Lymphoma, Emory University, Yale University, Medical school, Physician, Education, Internal medicine, Friends, Temple University, Hematology, American Board of Internal Medicine, ABIM, American Society of Clinical Oncology, Baylor University, Cancer, Haemophilia, Prognosis, Partner (business rank), Mentorship, American Society of Hematology, Inner circle, Oncology, Baptists, American Board of Commissioners for Foreign Missions, Iron-deficiency anemia, Patient, Blood, School, BPA, Fellow, MD Anderson Cancer Center, California Community College Athletic Association, Anti-transglutaminase antibodies, Baylor College of Medicine, Diagnosis, Leukemia, American Society of Pediatric Hematology/Oncology, Society, Dentistry, Nursing, MD, Princeton University, Biology, Medicine

VERO BEACH, Fla., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James C. Lasker is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology.

Key Points: 
  • VERO BEACH, Fla., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James C. Lasker is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the field of Hematology-Oncology.
  • Dr. Lasker pursued higher education at Yale University where he earned a Bachelor of Science degree in Biology.
  • He also noted that oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
  • The doctor would like to dedicate this honor to his mentors, Monty Lane, MD; Ken Walker, MD; and Jimmie Harvey, MD.

CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations

Retrieved on: 
화요일, 9월 5, 2023
Oncology, Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Immortalised cell line, Upjohn, GMP, Amgen, IIT, Medical Affairs Bureau, University, Bureau of Oceans and International Environmental and Scientific Affairs, Blas, University of Maryland, College Park, GU, Record, American Society of Pediatric Hematology/Oncology, Dartmouth–Hitchcock Medical Center, Bladder cancer, Multimedia, Research, Priscilla Chan, Assistant, AbCellera, National Cancer Institute, Urology, Patient, Division, Oslo-Fergene, Hematology, IND, Sanofi, Indian Institutes of Technology, Growth, Merck Serono, SVP, Chemical engineering, Caregiver, Disease, Management, Nursing, Photocure, Seagen, Pfizer

View the full release here: https://www.businesswire.com/news/home/20230905869419/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230905869419/en/
    Ambaw Bellete, President and Chief Operating Officer, CG Oncology (Photo: Business Wire)
    “CG Oncology is at an important stage in our growth, advancing our late-stage clinical pipeline to address unmet medical needs in bladder cancer.
  • Ambaw, Swapnil and Vijay bring decades of experience and proven track records in developing immunotherapy agents from research to commercialization,” said Arthur Kuan, Chief Executive Officer, CG Oncology.
  • Previously, Vijay was the VP, Clinical Development and Medical Affairs and a member of the executive leadership team at AVEO.
  • He was also SVP of Scientific Affairs at FerGene, leading Medical Affairs, Clinical Operations, Regulatory and Clinical Development.

Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting

Retrieved on: 
목요일, 8월 31, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Genetics, Clinical Trials, Society, Mantle cell lymphoma, George R. Brown Convention Center, NHL, SOHO, American Society of Pediatric Hematology/Oncology, Hematological Cancer Research Investment and Education Act, Machine learning, Lymphoma, Annual general meeting, Artificial intelligence, Poster, AI, IND, Pharmaceutical industry, Lantern

Lantern expects to initiate Phase 1 clinical trials for LP-284 during Q4 of 2023.

Key Points: 
  • Lantern expects to initiate Phase 1 clinical trials for LP-284 during Q4 of 2023.
  • Details of the poster presentation are listed below and can be found on the SOHO website .
  • A full version of the poster will be available on Lantern’s website on September 11, 2023.
  • Lantern’s LP-284 program has been accelerated and de-risked using AI insights and biological modeling powered by RADR®.

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

Retrieved on: 
목요일, 8월 31, 2023
Actinium, Abstract, Relapse, SOHO, Refractory, Random phase approximation, American Society of Pediatric Hematology/Oncology, AML, Annual general meeting, Patient, NYSE

NEW YORK, Aug. 31, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details three abstracts accepted for poster presentation at the upcoming Society of Hematologic Oncology (SOHO) 2023 Annual Meeting, which will be held in Houston, September 6-9, 2023. 

Key Points: 
  • NEW YORK, Aug. 31, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details three abstracts accepted for poster presentation at the upcoming Society of Hematologic Oncology (SOHO) 2023 Annual Meeting, which will be held in Houston, September 6-9, 2023.
  • Details of the SOHO poster presentations:
    Poster Title: The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Retrieved on: 
목요일, 8월 24, 2023
PTCL, APRE, Pitié-Salpêtrière Hospital, Therapy, Oxford, Oxaliplatin, United States Air Force Scientific Advisory Board, American Society of Pediatric Hematology/Oncology, DNA, EORTC, National Cancer Institute, Acquisition, Treatment, European Organization of Supreme Audit Institutions, Sanofi, Rhône-Poulenc, Mathematics, Compensated emancipation, Medical device, Management, Cancer, Celgene, Aprea-Cuccaro clan, Research

Dr. Bizzari will replace Mr. Christian Schade, who is stepping down from the Board.

Key Points: 
  • Dr. Bizzari will replace Mr. Christian Schade, who is stepping down from the Board.
  • “We warmly welcome Dr. Jean-Pierre Bizzari to our Board of Directors.
  • “Jean-Pierre joins our Board as Chris Schade retires from his role as Chairman and member of the Board to focus on his other commitments.
  • Dr. Richard Peters has served as independent Director of Aprea since June 2020 and Chair of the Compensation Committee since November 2020.

Lymphoma Research Foundation to Honor Esteemed Lymphoma Physician Kara Kelly, MD at Annual Gala on September 28

Retrieved on: 
수요일, 8월 2, 2023
Lymphoma, SAB, University, Pediatrics, Therapy, Senior, Jacobs School of Medicine and Biomedical Sciences, Bone marrow, American Biographical Institute, John R. Oishei Children's Hospital, Children's Oncology Group, Cancer, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Buffalo, Research, Roswell Park, Biomedical sciences, Young adult, Hodgkin, Waldemar, LRF, MD, Patient, Division, American Society of Pediatric Hematology/Oncology, Hospital, Leukemia, Health, Ziegfeld Theatre (1969), Pharmaceutical industry, Nursing, Genmab

NEW YORK, Aug. 2, 2023 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF), the nation's largest non-profit organization dedicated exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services, will host its 2023 Annual Gala on Thursday, September 28, at the Ziegfeld Ballroom in New York City.

Key Points: 
  • Genmab will be presented with the Lymphoma Research Foundation's Corporate Leadership Award for excellence in development of differentiated antibody therapeutics.
  • Honored at this year's gala will be LRF Scientific Advisory Board (SAB) member Kara Kelly, MD, who will recieve LRF's Distinguished Leadership Award.
  • "I am so incredibly honored to be receiving the Distinguished Leadership Award from the Lymphoma Research Foundation.'
  • We are proud to support the important work of the Lymphoma Research Foundation in achieving our shared goals for patients."